This site will be converted to selected language via Google Language Translation tool. Institute is not responsible for any errors generated due to Automatic translation. For any clarification, may please contact the concerned department of ILBS
What is hepatocellular carcinoma?
Liver cancer or hepatocellular carcinoma (HCC) is among of the common malignant tumours in the world, with a global increasing annual incidence, as reported recently. Almost half of this increase has been attributed to hepatitis C virus (HCV), while a minimal or no increase has been related to hepatitis B virus (HBV) or alcoholic liver disease. Untreated HCC has a notoriously poor prognosis, with a median survival of one to eight months and a five year survival of around 3%.
What are the treatment options for liver cancer? Potentially curative surgical therapeutic options:
Partial hepatic resection of HCC with adequate margins
Liver transplantation for HCC
(However, only 30% to 40% of patients with HCC qualify for surgery, mostly due to advanced disease at presentation and poor hepatic function, rendering the majority of patients eligible only for palliation)